Evidence map›Paper›PMID 39920715›Full record

ArticleCardiovascular diabetology2025

Predicting cardiovascular outcomes in Chinese patients with type 2 diabetes by combining risk factor trajectories and machine learning algorithm: a cohort study.

Qi Huang, Xiantong Zou, Zhouhui Lian, Xianghai Zhou, Xueyao Han, Yingying Luo, Shuohua Chen, Yanxiu Wang, Shouling Wu, Linong Ji

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qi Huang *Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Xiantong Zou *Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Zhouhui LianWangxuan Institute of Computer Technology (WICT), Peking University, Beijing, 100044, China.
Xianghai ZhouDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Xueyao HanDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Yingying Luo *Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Shuohua ChenDepartment of Cardiology, Kailuan General Hospital, Tangshan, China.
Yanxiu WangDepartment of Cardiology, Kailuan General Hospital, Tangshan, China.
Shouling WuDepartment of Cardiology, Kailuan General Hospital, Tangshan, China. drwusl@163.com.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China. jiln@bjmu.edu.cn.

Funding

Beijing Nova Cross program Z211100002121169National Natural Science Foundation of China T2341011Special Fund for Young Scientists of National Science and Technology Major Project of China 2023ZD0508801
6 · The paper itself

Abstract

backgroundCardiovascular complications are major concerns for Chinese patients with type 2 diabetes. Accurately predicting these risks remains challenging due to limitations in traditional risk models. We aimed to develop a dynamic prediction model using machine learning and longitudinal trajectories of cardiovascular risk factors to improve prediction accuracy.

methodsWe included 16,378 patients from the Kailuan cohort, splitting them into training and testing datasets. Using baseline characteristics and changes over a four-year observation period, we developed the ML-CVD-C (Machine Learning Cardiovascular Disease in Chinese) score to predict 10-year cardiovascular risk, including cardiovascular death, nonfatal myocardial infarction, and stroke. We compared the discrimination and calibration of ML-CVD-C with models using only baseline variables (ML-CVD-C [base]), China-PAR (Prediction for ASCVD Risk in China), and PREVENT (Predict Risk of cardiovascular disease EVENTs). Risk stratification improvements were assessed through net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Transition analysis examined the changes in risk stratification over time.

resultsThe ML-CVD-C score achieved a C-index of 0.80 (95% CI: 0.78-0.82) in the testing cohort, significantly outperforming the ML-CVD-C (base) score, China-PAR, and PREVENT, which had C-index values of 0.62-0.65. ML-CVD-C also provided more accurate cardiovascular risk estimates, though all models tended to overestimate the prevalence of high-risk cases. Stratification by the ML-CVD-C score showed substantial improvement, with NRI gains of 57.7%, 44.1%, and 47.3%, and IDI gains of 10.1%, 7.9%, and 8.4% compared to the other three scores. Both the trajectory and machine learning algorithm contributed significantly to the enhancement of model performance. Transition analysis revealed that participants who remained in the same risk category or were reclassified to a lower category exhibited 22% and 86% reductions in cardiovascular risk compared to those reclassified to a higher risk category during the observation period.

conclusionsThe ML-CVD-C model, incorporating dynamic cardiovascular risk trajectories and a machine learning algorithm, significantly improves risk prediction accuracy for Chinese patients with diabetes. This model may serve as a valuable tool for more personalized cardiovascular risk management in type 2 diabetes.

Indexed as

Cardiovascular DiseasesDecision Support TechniquesDiabetes Mellitus, Type 2Machine LearningAgedChinaEast Asian PeopleFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPredictive Value of TestsPrognosisReproducibility of ResultsRisk AssessmentMachine learningRisk predictionTrajectoriesType 2 diabetes

Identifiers

PMID39920715
PMCPMC11806858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.